Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia flag Australia · Delayed Price · Currency is AUD
9.99
-0.06 (-0.60%)
Jun 26, 2026, 4:10 PM AEST

Clinuvel Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Clinuvel Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $22.91. The average 1-year stock price forecast is 129.33% higher than the current stock price, while the lowest is $13.00 (+30.13%) and the highest is $39.20 (+292.39%).

Price Target: $22.91 (+129.33%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$13.00$22.91$22.00$39.20
Change+30.13%+129.33%+120.22%+292.39%
* Price targets were last updated on May 25, 2026.

Analyst Ratings

The average analyst rating for Clinuvel Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Apr '26May '26Jun '26
Strong Buy777777
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total888888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Bell Potter
Bell Potter
Buy
Maintains
$19.00$17.00
BuyMaintains$19.00$17.00+70.17%May 25, 2026
Jefferies
Jefferies
Buy
Maintains
$39.20
BuyMaintains$39.20+292.39%Apr 24, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$32.84$27.90
BuyMaintains$32.84$27.90+179.28%Mar 2, 2026
Morgans
Morgans
Buy
Maintains
$13.00
BuyMaintains$13.00+30.13%Feb 27, 2026
MA Financial Group
MA Financial Group
Buy
Maintains
$23.29
BuyMaintains$23.29+133.13%Feb 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
99.46M
from 95.02M
Increased by 4.68%
Revenue Next Year
105.36M
from 99.46M
Increased by 5.93%
EPS This Year
0.72
from 0.72
Decreased by -0.32%
EPS Next Year
0.77
from 0.72
Increased by 6.92%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingJun 30, 2021Jun 30, 2022Jun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026
Revenue
48.32M65.72M78.32M88.18M95.02M99.46M
Revenue Growth
48.37%36.02%19.17%12.59%7.76%4.68%
Gross Profit
44.15M56.47M70.80M80.45M86.54M92.13M
Gross Margin
91.36%85.92%90.40%91.23%91.08%92.63%
Operating Income
28.57M35.55M44.13M48.57M45.76M40.34M
Net Income
24.73M20.88M30.60M35.64M36.17M35.97M
EPS
----0.720.72
EPS Growth
----2.87%-0.32%
Forward PE
78.0226.1128.3421.4913.1613.96
Dividend / Share
0.030.040.050.050.050.06
Dividend Growth
-60.00%25.00%--22.28%
Free Cash Flow
8.06M33.25M32.33M23.45M29.93M31.65M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue202620272028
High104.8M
Avg99.5M
Low96.1M

Revenue Growth

Revenue Growth202620272028
High
10.3%
Avg
4.7%
Low
1.1%

EPS Forecast

EPS202620272028
High0.82
Avg0.72
Low0.59

EPS Growth

EPS Growth202620272028
High
14.1%
Avg
-0.3%
Low
-17.8%